2015 American Transplant Congress
CPRA Values Are Substantially Increased for Some Candidates Subsequent to Inclusion of Unacceptable C-locus (UA-C) Antigens While Listing Practices Remain Unchanged
1UNOS, Richmond; 2Emory University Hospital, Atlanta; 3Stanford University, Palo Alto.
Background: CPRA is the % of deceased donors expected to have one or more UAs with a given candidate. Prior to 12/5/13, candidates with UA-C…2015 American Transplant Congress
Immunoglobulin G Donor-Specific Anti-HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
Experimental and clinical data suggest that antibodies have different pathogenicities according to their IgG subclasses. We investigated the association between IgG subclasses of circulating anti-HLA…2015 American Transplant Congress
De Novo Donor-Specific HLA Antibodies After Kidney Transplantation Are Associated With Donation After Circulatory Death and HLA-DQ Mismatch
Introduction: De novo donor-specific HLA-antibodies (dnDSA) have been associated with rejection and inferior kidney graft survival. The purpose of this study was to investigate the…2015 American Transplant Congress
C1q Reactivity and IgG Subtypes After HLA Antibody Removal Therapy With Carfilzomib in Thoracic Transplant Recipients
Univ of Pittsburgh, Pittsburgh.
Conventional therapies for antibody removal consisting of plasma exchange with IVIG and Rituximab are partially effective in desensitization protocols and for treatment of antibody mediated…2015 American Transplant Congress
A Specific Inhibitor of C1s, TNT003, Prevents Complement-Mediated Enhancement of Monocyte Adhesion to Endothelium in Response to HLA Antibodies
HLA antibody (Ab) mediated complement activation on endothelial cells (EC) is likely a critical driver of antibody-mediated inflammation. Production of complement anaphylatoxins by HLA antibodies…2015 American Transplant Congress
Clinical Relevance of C3d-Binding Donor-Specific Antibodies in Late Kidney Allograft Failure
Background: The objective of this study was to investigate the prognostic value of C3d-binding donor-specific antibodies (DSA) in determining late kidney allograft failure.Methods: 1048 patients…2015 American Transplant Congress
Repeat Donor HLA Mismatch Antigens and Kidney Transplant Outcome
Background: Historically, poorer outcome has been reported in kidney re-transplant patients with repeat HLA mismatch antigens. Transplant practice has evolved. Risk of repeat mismatch antigen…2015 American Transplant Congress
Clinical Significance of Estimated DSA MFI Values at 1,000 C1q MFI for Differentiation Between Harmful and Harmless DSA
INTRODUCTIONControl of chronic antibody mediated rejection (CAMR) is essential for further improvement of long-term graft survival. Early detection of de novo donor specific antibodies (DSA)…2015 American Transplant Congress
Impact of Positive Crossmatch Due to Non-HLA Antibodies on Graft Outcomes in Renal Transplantation
Houston Methodist Hospital, Houston, TX.
It is widely recognized that a positive allogeneic crossmatch (+alloXM) due to pre-existing human leukocyte antigen (HLA) antibodies is associated with early rejection episodes. However,…2015 American Transplant Congress
Assessment of Circulating HLA-Specific Alloreactive Memory B Cells Reveals Surreptitious Immunized Kidney Transplant Recipients at High Risk of Antibody-Mediated Rejection
Even though current bead-based multiplex techniques enable an accurate assessment of circulating HLA-specific antibodies, a more comprehensive study of the humoral alloimmune response through the…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 47
- Next Page »